You are not logged in.

Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy

Deng, Junli, Wang, Li, Ni, Jie, Beretov, Julia, Wasinger, Valerie, Wu, Duojia, Duan, Wei, Graham, Peter and Li, Yong 2016, Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy, Expert review of proteomics, vol. 13, no. 10, pp. 905-915, doi: 10.1080/14789450.2016.1233065.

Attached Files
Name Description MIMEType Size Downloads

Title Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy
Author(s) Deng, Junli
Wang, Li
Ni, Jie
Beretov, Julia
Wasinger, Valerie
Wu, Duojia
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Graham, Peter
Li, Yong
Journal name Expert review of proteomics
Volume number 13
Issue number 10
Start page 905
End page 915
Total pages 11
Publisher Taylor & Francis
Place of publication Abingdon, Eng.
Publication date 2016-09-21
ISSN 1744-8387
Keyword(s) Mass spectrometry
biomarker
chemoresistance
ovarian cancer
proteomics
Summary INTRODUCTION: Chemoresistance is a major challenge to current ovarian cancer chemotherapy. It is important to identify biomarkers to distinguish chemosensitive and chemoresistant patients. AREAS COVERED: We review the medical literature, discuss MS-based technologies with respect to chemoresistant ovarian cancer and summarize the promising chemoresistant biomarkers identified. In addition, the challenges and future perspectives of biomarker discovery research are explored. With the employment of mass spectrometry-based (MS-based) proteomics, biomarker discovery of ovarian cancer has made great progress in the last decade. Many potential biomarkers were identified by MS-based proteomics technologies, some of which have been validated for further extensive studies in clinical settings. Expert commentary: The discovery of chemoresistant biomarkers is a newly developing area and may provide a clue for predicting chemotherapeutic response and discover therapeutic targets for paving the way of personalized medicine. Multiple complementary MS-based proteomics approaches hold promise for finding novel therapeutic targets in ovarian cancer treatment.
Language eng
DOI 10.1080/14789450.2016.1233065
Field of Research 111207 Molecular Targets
0601 Biochemistry And Cell Biology
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30086871

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 65 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Fri, 17 Feb 2017, 14:12:52 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.